查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790180

美國Dupixent 市場規模、佔有率和趨勢分析報告：按適應症、分銷管道、地區和細分市場預測，2025 年至 2033 年

U.S. Dupixent Market Size, Share & Trends Analysis Report By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

美國Dupixent 市場摘要

預計 2024 年美國Dupixent 市場規模為 103.9 億美元，預計 2033 年將達到 168.2 億美元，2025 年至 2033 年的複合年成長率為 5.47%。由於醫療保健涵蓋範圍廣，美國主導市場成長。

美國Dupixent 產業的發展受到異位性皮膚炎、氣喘和伴隨鼻息肉的慢性鼻竇炎 (CRSwNP) 等慢性發炎性疾病盛行率上升的推動。 FDA 於 2024 年 9 月核准Dupixent 用於治療慢性阻塞性肺病(COPD)，尤其是青少年患者，這擴大了該藥物的治療範圍。

Dupixent 是一種針對白細胞介素4 (IL-4) 和白細胞介素13 (IL-13) 路徑的單株抗體，旨在滿足中度至重度發炎性疾病中尚未滿足的臨床需求。它是美國市場領先的生物製藥，在治療異位性皮膚炎和重度氣喘方面已被證實有效。

醫療保健基礎設施和支出趨勢正在推動這種藥物的普及。預計到2023年，美國的醫療保健支出將達到4.9兆美元，這得益於生物製藥的廣泛使用和專科護理需求的不斷成長。然而，由於有2,600萬名用戶沒有醫療保險，報銷差距仍是市場准入的限制因素。儘管有這些限制，但20%的患者使用的遠端醫療正在改善都市區的醫療可近性。相較之下，佔人口19%的農村地區仍面臨醫療可近性的限制。

美國65歲以上人口已達5,800萬，人口老化加劇了慢性阻塞性肺病（COPD）的發生率，進一步拉動了市場需求。此外，由於環境因素，異位性皮膚炎和氣喘病例每年以2%的速度成長，這也推動了市場的成長。

Dupixent 可皮下給藥，其安全性優於皮質類固醇，從而提高了患者的依從性。賽諾菲和市場支持的真實世界證據研究得到了新的研發管線創新（包括嗜伊紅性食道炎的創新）、最佳化的給藥方案和擴大的生產能力的支持。然而，高昂的治療費用和服務欠缺地區的有限覆蓋仍然是一項挑戰。我們正在實施策略合作夥伴關係和患者支援計劃以解決這些障礙，這將有助於公司在 2033 年之前保持持續的成長勢頭。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章美國Dupixent 市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析-波特五力分析
    • PESTLE分析
    • 管道分析
    • 專利到期分析
    • 定價分析

第4章：美國Dupixent 市場（按適應症、估計和趨勢分析）

  • 2024 年及 2033 年各適應症市場佔有率
  • 細分儀表板：依指示
  • 2021 年至 2033 年市場規模、預測與趨勢分析（按適應症）
  • 異位性皮膚炎（AD）
  • 氣喘
  • 慢性鼻竇炎伴隨鼻息肉（CRSwNP）
  • 慢性阻塞性肺病（COPD）
  • 其他

第5章：美國Dupixent 市場通路預測及趨勢分析

  • 2024 年和 2033 年按分銷管道分類的市場佔有率
  • 細分儀表板：按分銷管道
  • 2021 年至 2033 年按分銷管道分類的市場規模、預測和趨勢分析
  • 醫院藥房
  • 零售藥局
  • 其他

第6章 競爭態勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Sanofi
    • Regeneron
Product Code: GVR-4-68040-660-4

U.S. Dupixent Market Summary

The U.S. dupixent market size was estimated at USD 10.39 billion in 2024 and is projected to reach USD 16.82 billion by 2033, growing at a CAGR of 5.47% from 2025 to 2033. The market growth dominates due to high healthcare access in the U.S.

The U.S. dupixent industry is driven by the rising prevalence of chronic inflammatory conditions, including atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps (CRSwNP). The recent FDA approval for chronic obstructive pulmonary disease (COPD) in September 2024, particularly in adolescent patients, has expanded the drug's therapeutic scope.

Dupixent, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13) pathways, addresses unmet clinical needs in moderate-to-severe inflammatory diseases. Its demonstrated efficacy in atopic dermatitis and severe asthma has positioned it as a leading biologic in the U.S. market.

Healthcare infrastructure and expenditure trends support the drug's adoption. The U.S. recorded USD 4.9 trillion in healthcare spending in 2023, driven by increasing biologic uptake and demand for specialty care. However, 26 million uninsured Americans and reimbursement gaps remain a constraint on market reach. Despite these limitations, telehealth adoption, utilized by 20% of patients, has improved access in urban settings. In contrast, rural areas, which account for 19% of the population, continue to face access limitations.

The aging population, with 58 million Americans over the age of 65, is contributing to rising COPD prevalence, further supporting demand. In addition, the annual 2% rise in atopic dermatitis and asthma cases, largely due to environmental factors, reinforces market growth.

Dupixent's subcutaneous administration and favorable safety profile compared to corticosteroids improve patient compliance. Real-world evidence studies, backed by Sanofi and the market, are supported by emerging pipeline innovations such as eosinophilic esophagitis, optimized dosing regimens, and expanded manufacturing capacity. However, high treatment costs and coverage limitations in underserved regions pose challenges. Strategic collaborations and patient assistance programs are being implemented to address these barriers, sustaining growth momentum through 2033.

U.S. Dupixent Market Report Segmentation

This report forecasts revenue growth for the U.S. and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. dupixent market report based on indication and distribution channel:

  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Atopic Dermatitis (AD)
  • Asthma
  • Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
  • Chronic Obstructive Pulmonary Disease (COPD)
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Indication
    • 1.2.2. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Dupixent Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis
    • 3.3.4. Patent Expiry Analysis
    • 3.3.5. Pricing Analysis

Chapter 4. U.S. Dupixent Market: Indication Business Analysis

  • 4.1. Indication Market Share, 2024 & 2033
  • 4.2. Indication Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 4.4. Atopic Dermatitis (AD)
    • 4.4.1. Atopic Dermatitis (AD) Market, 2021 - 2033 (USD Billion)
  • 4.5. Asthma
    • 4.5.1. Asthma Market, 2021 - 2033 (USD Billion)
  • 4.6. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
    • 4.6.1. Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) Market, 2021 - 2033 (USD Billion)
  • 4.7. Chronic Obstructive Pulmonary Disease (COPD)
    • 4.7.1. Chronic Obstructive Pulmonary Disease (COPD) Market, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Dupixent Market: Distribution Channel Business Analysis

  • 5.1. Distribution Channel Market Share, 2024 & 2033
  • 5.2. Distribution Channel Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
  • 5.4. Hospital Pharmacies
    • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.5. Retail Pharmacies
    • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

  • 6.1. Participant Overview
  • 6.2. Company Market Position Analysis
  • 6.3. Company Categorization
  • 6.4. Strategy Mapping
  • 6.5. Company Profiles/Listing
    • 6.5.1. Sanofi
      • 6.5.1.1. Overview
      • 6.5.1.2. Financial Performance
      • 6.5.1.3. Product Benchmarking
      • 6.5.1.4. Strategic Initiatives
    • 6.5.2. Regeneron
      • 6.5.2.1. Overview
      • 6.5.2.2. Financial Performance
      • 6.5.2.3. Product Benchmarking
      • 6.5.2.4. Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 U.S. Dupixent market, by region, 2021 - 2033 (USD Billion)
  • Table 4 U.S. Dupixent market, by indication, 2021 - 2033 (USD Billion)
  • Table 5 U.S. Dupixent market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 U.S. Dupixent market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and application outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Dupixent market dynamics
  • Fig. 12 Dupixent market: Porter's five forces analysis
  • Fig. 13 Dupixent market: PESTLE analysis
  • Fig. 14 Product market, 2021 - 2033 (USD Billion)
  • Fig. 15 Atopic Dermatitis (AD) market, 2021 - 2033 (USD Billion)
  • Fig. 16 Asthma market, 2021 - 2033 (USD Billion)
  • Fig. 17 Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) market, 2021 - 2033 (USD Billion)
  • Fig. 18 Chronic Obstructive Pulmonary Disease (COPD) market, 2021 - 2033 (USD Billion)
  • Fig. 19 Others market, 2021 - 2033 (USD Billion)
  • Fig. 20 Distribution Channel market, 2021 - 2033 (USD Billion)
  • Fig. 21 Hospital Pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 22 Retail Pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 23 Others market, 2021 - 2033 (USD Billion)
  • Fig. 24 Company categorization
  • Fig. 25 Company market position analysis
  • Fig. 26 Strategic framework